Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes

Investigative Ophthalmology and Visual Science

Volumn 53, Issue 4, 2012, Pages 2349-2353

  Akagi Kurashige, Yumiko ^a   Kumagai, Kyoko ^a   Yamashiro, Kenji ^a   Nakanishi, Hideo ^a   Nakata, Isao ^a   Miyake, Masahiro ^a   Tsujikawa, Akitaka ^a   Moriyama, Muka ^b   Ohno Matsui, Kyoko ^b   Mochizuki, Manabu ^b   Yamada, Ryo ^a   Matsuda, Fumihiko ^a   Yoshimura, Nagahisa ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGE; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; EYE AXIS LENGTH; FEMALE; GENDER; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HIGH MYOPIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHOROIDAL NEOVASCULARIZATION; FEMALE; HUMANS; MALE; MYOPIA; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861180637     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-9405     Document Type: Article

References (35)

1. Sawada A, Tomidokoro A, Araie M, Iwase A, Yamamoto T. Refractive errors in an elderly Japanese population: the Tajimi study. Ophthalmology. 2008;115:363-370, e363. http://www.ophsource.org/periodicals/ophtha/article/S0161-6420%2807%2900379. Accessed March 29, 2012.
2. Wong TY, Foster PJ, Hee J, et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci. 2000;41:2486-2494.
3. Kempen JH, Mitchell P, Lee KE, et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol. 2004;122:495-505.
4. Hayashi K, Ohno-Matsui K, Shimada N, et al. Long-term pattern of progression of myopic maculopathy a natural history study. Ophthalmology. 2010; 117:1595-1611.
5. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: a 10-year follow-up. Ophthalmology. 2003; 110:1297-1305.
6. Hayashi K, Ohno-Matsui K, Yoshida T, et al. Characteristics of patients with a favorable natural course of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005; 243:13-19.
7. Nakanishi H, Yamada R, Gotoh N, et al. A genome-wide association analysis identified a novel susceptible locus for pathological myopia at 11q24.1. PLoS Genet. 2009;5:e1000660. http://www.plosgenetics.org/article/info%3Adoi%2F10.1371%2Fjournal.pgen.100. Accessed March 29, 2012.
8. Solouki AM, Verhoeven VJ, van Duijn CM, et al. A genomewide association study identifies a susceptibility locus for refractive errors and myopia at 15q14. Nat Genet. 2010;42: 897-901.
9. Hysi PG, Young TL, Mackey DA, et al. A genome-wide association study for myopia and refractive error identifies a susceptibility locus at 15q25. Nat Genet. 2010;42:902-905.
10. Hayashi H, Yamashiro K, Nakanishi H, et al. Association of 15q14 and 15q25 with high myopia in Japanese. Invest Ophthalmol Vis Sci. 2011;52:4853-4858.
11. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study. Ophthalmology. 2007;114: 2190-2196.
12. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol. 2009; 147:84-93, e81. http://www.ajo.com/. Accessed March 29, 2012.
13. Wu PC, Chen YJ. Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye (Lond). 2009;23:2042-2045.
14. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 2000;37:443-448.
15. Shahbazi M, Fryer AA, Pravica V, et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2002;13:260-264.
16. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003;63:812-816.
17. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production, Cytokine. 2000;12:1232-1235.
18. Mori K, Horie-Inoue K, Gehlbach PL, et al. Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology. 2010;117:928-938.
19. Lin JM, Wan L, Tsai YY, et al. Vascular endothelial growth factor gene polymorphisms in age-related macular degeneration. Am J Ophthalmol. 2008;145:1045-1051.
20. Fang AM, Lee AY, Kulkarni M, Osborn MP, Brantley MA Jr. Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. Mol Vis. 2009; 15:2710-2719.
21. Janik-Papis K, Zaras M, Krzyzanowska A, et al. Association between vascular endothelial growth factor gene polymorphisms and age-related macular degeneration in a Polish population. Exp Mol Pathol. 2009;87:234-238.
22. Kangas-Kontio T, Vavuli S, Kakko SJ, et al. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol. 2009;93:1401-1406.
23. Chun MY, Hwang HS, Cho HY, et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2010;95:3547-3551.
24. Salvarani C, Boiardi L, Casali B, et al. Vascular endothelial growth factor gene polymorphisms in Behcet's disease. J Rheumatol. 2004;31:1785-1789.
25. Landgren S, Palmer MS, Skoog I, et al. No association of VEGF polymorphisms with Alzheimer's disease. Neuromolecular Med. 2010; 12:224-228.
26. Freathy RM, Weedon MN, Shields B, et al. Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. JOP. 2006;7:295-302.
27. Fernandez-Robredo P, Maestre SR, Zarranz-Ventura J, Mulero HH, Salinas-Alaman A, Garcia-Layana A. Myopic choroidal neovascularization genetics. Ophthalmology. 2008;115:1632, 1632. e1. http://www.ophsource.org/periodicals/ophtha/article/S0161-6420(08)00226-1/. Accessed March 29, 2012.
28. Nakanishi H, Gotoh N, Yamada R, et al. ARMS2/HTRA1 and CFH polymorphisms are not associated with choroidal neovascularization in highly myopic eyes of the elderly Japanese population. Eye (Lond). 2010;24:1078-1084.
29. Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol. 1999;154:1743-1753.
30. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
31. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
32. Ishida S, Yamashiro K, Usui T, et al. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9:781-788.
33. Ishida S, Usui T, Yamashiro K, et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med. 2003;198:483-489.
34. Bates DO, Cui TG, Doughty JM, et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is downregulated in renal cell carcinoma. Cancer Res. 2002;62:4123-4131.
35. The International HapMap Project. International HapMap Consortium. Nature. 2003;426:789-796.